Simulation of the economic impact of introducing rivaroxaban in a high-complexity hospital for venous thromboembolism prophylaxis
DOI:
https://doi.org/10.30968/rbfhss.2024.153.1153Abstract
Objective: this work aims to simulate the economic impact of the introduction of rivaroxaban for venous thromboembolism (VTE) prophylaxis, when compared to the therapeutic options used in the institution (unfractionated heparin and enoxaparin), in the period from January to February 2022. Methods: In a retrospective study, we analyzed the possibility of replacing the prophylaxis used in the institution with prophylaxis with rivaroxaban based on the analysis of data from the electronic medical record system, taking into account the length of stay, the medications prescribed and compliance with the institutional protocol. Patients prescribed medication for VTE prophylaxis and indicated according to progress in the medical record were included, excluding those using non-pharmacological prophylaxis. Patients with contraindications to the use of rivaroxaban, such as pregnancy and liver impairment, were also excluded. Monte Carlo Simulation was used to calculate the cost of treatment with DOACs (Direct Oral Anticoagulants), using the medicines acquisition values during the study period, and a decision tree was constructed. Results: A total of 157 patients who were prescribed one of the heparins were evaluated. Of these patients, 98 (62.4%) could undergo prophylaxis with rivaroxaban as they had no contraindication to this treatment (price recorded in January/February 2022: R$ 0.23). This new prophylaxis would generate savings of up to 98.4% for enoxaparin 40 mg (price recorded in January/February: R$ 14.26), the item that had the highest consumption, corresponding to 71.4% of patients who could use it rivaroxaban. Conclusion: The implementation of rivaroxaban for venous thromboembolism prophylaxis replacing enoxaparin proved to be beneficial in terms of costs for the hospital, which suggests that more studies should be carried out in order to increase the robustness of results and support the incorporation of this technology in the institution.
Downloads
References
Burihan MC, et al. Consenso e atualização na profilaxia e no tratamento do tromboembolismo venoso. 1.ed. Rio de Janeiro: Guanabara Koogan, 2019.
Bauer KA, Lip GH. Overview of the causes of venous thrombosis. UpToDate. Disponível em: https://www.uptodate.com/contents/over-view-of-the-causes-of-venous-thrombosis?search=tromboembolismo%20venoso&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1. Acesso em: 20 maio 2023.
Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of Venous Thromboembolism. Chest, 2008;133(6):63. DOI:10.1378/chest.08-0656.
Dobesh PP, Fanilos J. New Oral Anticoagulants for the Treatment of Venous Thromboembolism: understanding differences and similarities. Drugs. Spr Sci and Bus Media LLC. 2014;74(17):17. DOI:10.1007/s40265-014-0301-x.
Hull, RD, Garcia DA; Burnett, AE. Heparin and LMW heparin: Dosing and adverse effects. UpToDate. Disponível em: https://www.uptodate.com/contents/heparin-and-lmw-heparin-dosing-and-adverse-effects?topicRef=1370&source=see_link#H437372. Acesso em: 30 maio 2023
Linchtenstein A, et al. Tromboembolismo venoso (TEV). Protocolo Institucional do Instituto Central do Hospital das Clínicas da Faculdade de Medicina da USP de São Paulo, versão 2, 15 mar. 2022.
Cohen, AT et al. Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis. PLoS One. 2015; 10(12). DOI: 10.1371/journal.pone.0144856.
Key NS, Bohlke K, Falanga A. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: asco clinical practice guideline update summary. J Onc Pract. 2019;15(12):5. DOI:10.1200/jop.19.00368.
Brasil. Agência Nacional de Vigilância Sanitária (ANVISA). Bulário Eletrônico. Disponível em: https://consultas.anvisa. gov.br/#/bulario/. Acesso em: 28 maio 2023.
Lin S, Wang Y, Zhang L, et al. Dabigatran must be used carefully: literature review and recommendations for management of adverse events. Drug Dsg, Develop And Therapy. 2019;13:8. DOI:10.2147/dddt.s203112.
Diamantopoulos A, Lees M, Weels PS, et al. Cost-effectiveness of rivaroxaban versus enoxaparin for the prevention of postsurgical venous thromboembolism in Canada. Thromb And Haemos. 2010;104(10):12. DOI: 10.1160/th10-01-0071.
Ghanima W, Atar D, Sandset PM. Nye perorale antikoagulasjonsmidler – en oversikt. Tids For Den Nor Legeforening. 2013;133(18):6. DOI: 10.4045/tidsskr.12.1111.
Brasil. Ministério da Saúde. Secretaria de Ciência, tecnologia e insumos estratégicos. Diretrizes metodológicas: Diretriz de avaliação econômica. Brasília, 2014.
Maia LM. et al. A importância da ferramenta curva ABC no gerenciamento de estoque [artigo]. Anais do IX Simpósio de Engenharia de Produção de Sergipe. São Cristóvão, 2017.
BRASIL. Lei nº 14133, de 01 de abril de 2021. Lei de Licitações e Contratos Administrativos. 61-F. ed. Brasília, DF: Diário Oficial da União, 01 abr. 2021. Seção 1.
Paula RR. Método de Monte Carlo e aplicações [monografia]. Universidade Federal Fluminense, Volta Redonda – RJ, 2014. Disponível em: https://app.uff.br/riuff/handle/1/4180. Acesso em: 07 abril 2024.
Velaz OA, Bueno, IC. Rivaroxaban frente a enoxaparina como tromboprofilaxis em cirugía ortopédica y traumatología: um metaanálisis. Rev Esp Cir Ortop Traumatol. 2023:11. DOI: 10.1016/j.recot.2023.09.005
Gulati S, Eckman MH. Anticoagulant Therapy for Cancer-Associated Thrombosis : A Cost-Effectiveness Analysis. Ann Intern Med. 2023;176(1):9. DOI: 10.7326/M22-1258
Xu J, Chang D, Chui J, et al. The efficacy and cost-effectiveness of enoxaparin versus rivaroxaban in the prevention of venous thromboembolism following total hip or knee arthroplasty: A meta-analysis. J Orthop. 2022;30:6. DOI: 10.1016/j.jor.2022.02.003
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Authors
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The authors hereby transfer, assign, or otherwise convey to RBFHSS: (1) the right to grant permission to republish or reprint the stated material, in whole or in part, without a fee; (2) the right to print republish copies for free distribution or sale; and (3) the right to republish the stated material in any format (electronic or printed). In addition, the undersigned affirms that the article described above has not previously been published, in whole or part, is not subject to copyright or other rights except by the author(s), and has not been submitted for publication elsewhere, except as communicated in writing to RHFHSS with this document.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC-BY-NC-ND) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Serlf-archiving policy
This journal permits and encourages authors to post and archive the final pdf of the articles submitted to the journal on personal websites or institutional repositories after publication, while providing bibliographic details that credit its publication in this journal.
